COPD News

No significant change in COPD prevalence occurred between 2011 and 2021 in the U.S., according to data from the CDC published in Morbidity and Mortality Weekly Report.

Incidence rates for several respiratory viruses, including influenza and respiratory syncytial virus, declined during vs. before the COVID-19 pandemic, according to study results published in Thorax.

Adults with moderate to severe COPD and type 2 inflammation receiving dupilumab vs. placebo had fewer exacerbations and improved lung function at 52 weeks, according to topline results from the phase 3 NOTUS trial.

Cardiovascular disease often occurs among patients with both COPD and obstructive sleep apnea, but there are little data evaluating how the overlap impacts disease severity, according to a presentation at the 2023 GOLD COPD conference.

During the month of November, clinicians, lung organizations and patients with COPD come together every year to spread awareness of COPD and its symptoms.

Individuals aged 15 to 50 years faced heightened odds for COPD if they had been exposed to household air pollution and elevated ambient ozone levels, according to results published in Thorax.

Patients with severe alpha-1 antitrypsin deficiency had improved survival with intravenous plasma-purified alpha-1 antitrypsin therapy, according to results published in American Journal of Respiratory and Critical Care Medicine.

To reflect advances in COPD diagnosis and treatment, the 2024 Global Initiative for Chronic Obstructive Lung Disease report features both new and revised sections.

Intranasal corticosteroids did not impact COVID-19 mortality in patients with asthma, COPD or neither, but they did reduce the risk for all-cause mortality, according to study results published in Annals of Allergy, Asthma & Immunology.

ANAHEIM, Calif — Benralizumab lowered the rate of COPD exacerbations among patients with asthma and COPD after 1 year, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.